000 | 01926 a2200589 4500 | ||
---|---|---|---|
005 | 20250515065251.0 | ||
264 | 0 | _c20070627 | |
008 | 200706s 0 0 eng d | ||
022 | _a0918-6158 | ||
024 | 7 |
_a10.1248/bpb.30.1021 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aVenkatesh, Pilla Reddy | |
245 | 0 | 0 |
_aIn vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. _h[electronic resource] |
260 |
_bBiological & pharmaceutical bulletin _cMay 2007 |
||
300 |
_a1021-4 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAdministration, Oral |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBenzimidazoles _xblood |
650 | 0 | 4 | _aBiological Availability |
650 | 0 | 4 | _aCaco-2 Cells |
650 | 0 | 4 |
_aCell Membrane Permeability _xdrug effects |
650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
650 | 0 | 4 | _aDogs |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 |
_aEnzyme Inhibitors _xblood |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHalf-Life |
650 | 0 | 4 | _aHistone Deacetylase Inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydroxamic Acids _xblood |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMetabolic Detoxication, Phase I |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred BALB C |
650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
650 | 0 | 4 |
_aPyrroles _xblood |
650 | 0 | 4 | _aPyrrolidines |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Wistar |
650 | 0 | 4 | _aVorinostat |
700 | 1 | _aGoh, Evelyn | |
700 | 1 | _aZeng, Peizi | |
700 | 1 | _aNew, Lee Sun | |
700 | 1 | _aXin, Liu | |
700 | 1 | _aPasha, Mohammed Khalid | |
700 | 1 | _aSangthongpitag, Kanda | |
700 | 1 | _aYeo, Pauline | |
700 | 1 | _aKantharaj, Ethirajulu | |
773 | 0 |
_tBiological & pharmaceutical bulletin _gvol. 30 _gno. 5 _gp. 1021-4 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1248/bpb.30.1021 _zAvailable from publisher's website |
999 |
_c17021310 _d17021310 |